A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency
Latest Information Update: 15 Jun 2021
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Bacteraemia; Bacterial infections; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pneumonia; Pyelonephritis; Urinary tract infections
- Focus Adverse reactions
- Sponsors Rempex Pharmaceuticals
- 07 Jun 2021 Results of a population pharmacokinetic analysis using pooled data from two Phase 1 (Rempex501 & Rempex504) and two Phase 3 studies ( TANGO 1 & TANGO 2) published in the Antimicrobial Agents and Chemotherapy
- 09 Mar 2020 Results published in the Journal of Clinical Pharmacology
- 08 Oct 2017 Results presented at the IDWeek 2017